Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by amyloid-beta (Aβ) plaques and hyperphosphorylated tau tangles, leading to cognitive decline. It affects 50 million people globally, with projections of 152 million by 2050. The gut microbiota plays a crucial role in AD pathology, with altered microbial diversity linked to cognitive impairment. Research suggests that gut dysbiosis may contribute to AD progression through mechanisms involving neuroinflammation, oxidative stress, and the gut-brain axis (GBA). Diet significantly influences gut microbiota composition, with certain dietary patterns, such as the Mediterranean, DASH, MIND, and ketogenic diets, showing potential in reducing AD risk. Probiotics, prebiotics, and dietary fiber can modulate gut microbiota, influencing brain health and cognitive function. Studies indicate that specific microbial species, such as Akkermansia muciniphila, may have therapeutic potential in AD. However, the exact mechanisms and therapeutic applications of these interventions remain under investigation. This review highlights the complex interactions between diet, gut microbiota, and AD, emphasizing the need for further research to develop effective strategies for prevention and treatment.Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by amyloid-beta (Aβ) plaques and hyperphosphorylated tau tangles, leading to cognitive decline. It affects 50 million people globally, with projections of 152 million by 2050. The gut microbiota plays a crucial role in AD pathology, with altered microbial diversity linked to cognitive impairment. Research suggests that gut dysbiosis may contribute to AD progression through mechanisms involving neuroinflammation, oxidative stress, and the gut-brain axis (GBA). Diet significantly influences gut microbiota composition, with certain dietary patterns, such as the Mediterranean, DASH, MIND, and ketogenic diets, showing potential in reducing AD risk. Probiotics, prebiotics, and dietary fiber can modulate gut microbiota, influencing brain health and cognitive function. Studies indicate that specific microbial species, such as Akkermansia muciniphila, may have therapeutic potential in AD. However, the exact mechanisms and therapeutic applications of these interventions remain under investigation. This review highlights the complex interactions between diet, gut microbiota, and AD, emphasizing the need for further research to develop effective strategies for prevention and treatment.